Lundbeck earned $51.7M in settlements with generic makers over Lexapro patent

Clayton Utz 2019-02-27 10:09 pm By Christine Caulfield | Melbourne

Please login to bookmark

Danish pharmaceutical giant Lundbeck secured $51.7 million in settlements to end infringement litigation with three generic makers over its patent for the top-selling Lexapro, the company has revealed.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au